ArticleScientific reports2025
The role of ROSE-enhanced ERCP-guided biopsy in diagnosing biliary stricture.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To evaluate the diagnostic efficacy of rapid on-site evaluation (ROSE)-enhanced endoscopic retrograde cholangiopancreatography (ERCP)-guided biopsy for biliary strictures, and develop a predictive model for diagnostic accuracy. This retrospective study included 200 patients undergoing ERCP-guided biopsy (ROSE cohort, n = 100; NON-ROSE cohort, n = 100). Diagnostic performance metrics (accuracy, sensitivity, specificity, positive predictive value [PPV], negative predictive value [NPV]), specimen adequacy, biopsy attempts, procedure duration, and complications were compared between groups. Logistic regression identified independent predictors of diagnostic accuracy. A prediction model was developed and internally validated through receiver operating characteristic (ROC) curve analysis, calibration curves, decision curve analysis (DCA), and constructed as a nomogram. The ROSE cohort demonstrated significantly higher accuracy (92.0% vs. 78.0%), sensitivity (97.2% vs. 74.7%), and NPV (91.6% vs. 48.7%) (all P < 0.05). ROSE required fewer biopsy passes (2.43 vs. 3.61; P < 0.001), shorter sampling time (2.71 vs. 4.33 min; P < 0.001), without increased complications (P > 0.05). Multivariate analysis confirmed ROSE as an independent predictor (OR≈4.0, P = 0.032). The validated predictive model showed good discrimination (AUC≈0.80) and clinical utility. ROSE significantly enhances diagnostic yield and procedural efficiency in ERCP-guided biopsy for biliary strictures. The developed nomogram provides an evidence-based tool for individualized prediction, supporting clinical decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.